Drug Profile


Alternative Names: Amitiza; RU-0211; SPI-0211

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Sucampo Pharmaceuticals
  • Developer Sucampo Pharmaceuticals; Takeda
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Monounsaturated fatty acids; Prostaglandins; Small molecules
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Postoperative ileus

Most Recent Events

  • 21 Nov 2016 Sucampo Pharmaceuticals plans a phase III trial for chronic idiopathic Constipation in Japan (PO, Capsule) (JapicCTI163442)
  • 09 Nov 2016 Sucampo and Dr. Reddy's dismiss the patent litigation related to generic version of lubiprostone
  • 01 Nov 2016 Sucampo initiates a phase III pharmacokinetics trial in Healthy adult volunteers in USA (PO, Sprinkle) (NCT03010631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top